Aplastic Anaemia Genomics: Current data and interpretation
|
|
- Tamsin Glenn
- 6 years ago
- Views:
Transcription
1 An Academic Health Sciences Centre at the heart of a world city... Aplastic Anaemia Genomics: Current data and interpretation Austin G Kulasekararaj Consultant Haematologist King s College Hospital, London
2 Clonal Wars- clonal Force Awakens T cell clones (Immune) Escape clones- PNH, +8, 13q and 6pUPD Good Clones vs Bad clones Aged clones vs disease clones True vs Pseudo clonality Clonal Flux (Fluctuant/transient) Clonal elimination (spontaneous/therapy)- PNH and transplant (!)
3 AA associated with diseases of clonal hematopoiesis FANC AA/PNH FA VSAA SAA PIGA STAT3 PNH LGL (clonal or polyclonal) TERC, TERT,TINF2 RPS5, RPS11, RPS 19 DC NSAA RBDS5q- Low risk Hypo MDS MDS MDS/MPD High risk Hypo AML AML MDS/AML-type somatic mutations Adapted and modified from Young NS et al. Blood 26;18:
4 Del(13q) cells (%) Cytogenetic clones in AA that evade immune attack HSC WT c-myc Survivi 4 n CDK1 2 Trisomy 8 1 Changes in the proportion of del(13q) cells after IST in 8 patients Cytokin es CD8+ T cell clonal expansion Copy number neutral 6p loss of heterozygosity 2 8+ UPN 3 UPN 7 LOH del(13q) FISH (Peripheral blood) del(13q) FISH (Peripheral blood) 32.2% CTL CTL 4.% SSC-A CD11b SSC-A CD11b Del 13q 3 del(13q) FISH % Ch6, chromosome 6; CTL, cytotoxic T lymphocytes; HLA, human leukocyte antigen; Months from diagnosis HSC, GPI-AP, hematopoietic glycosylphosphatidylinositol-anchored stem cell; HSPC, hematopoietic protein; stem/progenitor FISH, fluorescent in situ hybridization; cell; UPN, LOH, unique loss patient of heterozygosity; number TCR, T cell receptor; WT1, Wilms 1. Sloand 3. Hosakawa EM et al. Blood K et al. 25;16: ; Haematologica 212;97: Katagiri T et al. tumor protein Blood 211;118: Hosakawa K et al. Haematologica 212;97: TCR 2 TCR TCR HSP C del(13q) FISH 12% CTL HLA* Recombinat 4 1 LOH 2 3 A*2:1 LOH FSC-A HLA ion of 6p A*2:6 CD55, CD59 FSC-A CD55, CD59 A*31:1 B*4:2 arms CTL CTL LOH del(13q) FISH % LOH LOH del(13q) FISH 12% 1 4
5 Frequency and incidence of mutations ASXL1 (n=12) DNMT3A (n=8) BCOR (n=6) One each of: SRSF2 U2AF1 TET2 MPL IKZF1 ERBB2 The median allele burden was 2% (range, %) All heterozygous except one hemizygous BCOR 41% of mutations had <1% clone Mutations detected were missense (n=12), nonsense (n=12), frameshift (n=6), non-frameshift deletion (n=1) and splice-site changes (n=1) UPN Gene Mutant allele burden (%) 142 DNMT3A 1.5 Non-synonymous SNV c.c5644t:p.r882c C>T p.w1356 X Variant class Nucleotide and protein change 7 ASXL1 2 Stopgain SNV c.g226t:p.e676x 81 ASXL1 3 Stopgain SNV c.t2324g:p.l775x 88 ASXL1 7 Frameshift deletion c.2126delc:p.a79fs 2 ASXL1 3 Frameshift insertion c.1927_1928insg:p.g643fs 16 ASXL1 3 Frameshift insertion c.2469_247insag:p.l823fs 17 ASXL1 3 Stopgain SNV c.t2468g:p.l823x 4 ASXL1 31 Non-frameshift deletion c.2894_2896del:p.965_966del 69 ASXL1 34 Stopgain SNV c.277t:p.r693x 79 ASXL1 36 Stopgain SNV c.g226t:p.e676x 66 ASXL1 37 Frameshift deletion c.2433delt:p.n811fs 6 ASXL1 38 Stopgain SNV c.c2242t:p.q748x 29 ASXL1 41 Stopgain SNV c.g468a:p.w1356x 129 DNMT3A 5 Non-synonymous SNV c.g227a:p.r736h 13 DNMT3A 5 Non-synonymous SNV c.g2645a:p.r882h Mutant allele burden = 41% 97 DNMT3A 7 Non-synonymous SNV c.c5644t:p.r882c 93 DNMT3A 8 Stopgain SNV C2311T:p.R771X 18 DNMT3A 31 Non-synonymous SNV c.c2644t:p.r882c 2 DNMT3A 42 Non-synonymous SNV c.c154g:p.l514v 64 DNMT3A 47 Non-synonymous SNV c.c2644t:p.r882c 21 BCOR 5 Stopgain SNV c.c526t:p.q176x 14 BCOR 5 Frameshift deletion c.476delc:p.p1587fs 73 BCOR 6 Frameshift insertion c.4834_4835insc:p.l1612fs 7 BCOR 14 Stopgain SNV c.t912g:p.y34x 94 BCOR 3 Splice site Splice site c.352-2a>g 33 BCOR 68 Stopgain SNV c.g4832a:p.w1611x 2 ERBB2 44 Non-synonymous SNV c.g922a:p.v38m 19 IKZF1 14 Non-synonymous SNV c.c64g:p.h214d 46 MPL 1 Non-synonymous SNV c.g1544t:p.w515l 1 SRSF2 2 Non-synonymous SNV c.c284t:p.p95l 5 TET2 5 Stopgain SNV c.c31t:p.q134x 67 U2AF1 19 Non-synonymous SNV c.c11a:p.s34y Bone marrow Skin Kulasekararaj AG et al. Blood 214;124:
6 AA (excluding PIGA mutations)? Do they predict risk of evolution to MDS? Disease duration Mutations (n=29) Wild type (n=121) <6 months (n=63) 9 54 P-value Transformation into MDS 3 3 <.3 Median mutant allele burden <1% 7 NA >6 months (n=87) 2 67 Transformation into MDS 8 3 <.2 Median mutant allele burden <1% Median follow-up 46 months (range, 1 36) Somatic mutation found in 29/15 (19%) In the presence of a somatic mutation: 4 NA 1. Risk of MDS = 11/29 (38%) compared with 6/121 (6%); P<.1 2. If disease duration >6 months, risk of MDS is 4% compared with 4% Kulasekararaj AG et al. Blood 214;124:
7 Monosomy 7 (% by FISH) Monosomy 7: Diverse origins 1 8 Control GCSF 4 ng/ml Postauto HSCT Donor leukemia Postcord Myeloid neoplasia Road to monosomy 7 Growth factors AA GCSF Kostmanns TPO mimetic Eltrombopag Transient -7 (disappears post-atg) Persistent -7 (MDS/AML) Patient UPN Stressed hematopoiesis Proliferative pressure Depleted stem cell pool Telomere loss Genomic instability Age/ sex Diagnosi s Initial therapy Disease duration (months) Respons e MC 73/M NSAA ATG + CSA 44 CR Normal Mutation(s) ASXL1 DNMT3A Clonal evolution RCMD/-7 35/F NSAA ATG + CSA 45 NR 45,XX,-7 ASXL1 RCMD/ /M VSAA ATG + CSA 2 NR Normal ASXL1 hmds/-7 31 RCMD- 83/M NSAA CSA 62 CR 45,XY,-7 DNMT3A 47 CR, complete response; CSA, cyclosporine A; GCSF, granulocyte-colony stimulating RAEB2-AML factor; hmds, hypoplastic MDS; HSCT, hematopoietic stem cell transplant; NR, non response; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; TPO, thrombopoietin; VAF, variable allele frequency Kulasekararaj AG et al. Blood 214;124: VAF 3 42
8 Lower VAF at diagnosis and its interpretation mutations presen Targeted sequencing of genes at diagnosis of aplastic anaemia (n=96) at None of them had mutations with VAF > Cautious use of mutation calling in clini by sequencing laboratories Yoshizato et al. NEJM 215 Kulasekararaj et al, Unpublished
9 Frequency Aged versus disease clones Prevalence of somatic mutations according to age Age (years) Somatic mutations that drive clonal expansion are common in the elderly and most frequently involve DNMT3A, TET2 or ASXL1, and are associated with increased Jaiswal S et al. N Engl J Med 214;371:
10 Clonal eradication: spontaneous or therapy MSD, n=12, 1% UD, n=33, 9.5% King s College Hospital, 215 FCC regimen Babushok et al. BJH 216, Marsh et al unpublished
11 Clonal size and frequency Mutational profile of AA and its evolution following IST 1 MDS Clinical Significance IST AA Time and disease course Age related clonal haemopoiesis Normal haemopoietic stem cell (HSC) Overlap AA/MDS CHIP Hypoplastic MDS or Overlap AA/MDS (?) Progression to MDS?Consider early allogeneic Recovery of normal haemopoiesis transplantation Frequency of four commonly mutated genes in AA from two studies 2,3 Kulasekararaj Yoshizato et et al. al. Top four genes DNMT3A 8.3% 8.4% Dysplastic HSC Dysplastic HSC with single mutation *BCORL1 not analysed NA-PIGA not done for the whole cohort VAF-variant allele frequency ASXL1 8% 6.2% BCOR/BCORL 1 4%* 9.3% PIGA N/A 7.5% Dysplastic HSC with multiple mutations CHIP-Clonal haemopoiesis of indeterminate potential 1. Mufti GJ et al. N Engl J Med 215;373: ; 2. IST-immunosuppressive therapy Median Kulasekararaj VAF AG et al. 2% Blood 214;124: ; 9.3% 3.
12 Acknowledgements Rayne Institute Tony Pagliuca Robin Ireland Victoria Potter Donal McLornan Kavita Raj Hugues Delavallade Joop Gaken Alexander Smith Jie Jiang Azim Mohamedali Shreyans Gandhi Syed Mian Nik Lea Steve Best Shahram Kordasti SAAWP
Clinical significance of acquired somatic mutations in aplastic anaemia
Int J Hematol (2016) 104:159 167 DOI 10.1007/s12185-016-1972-8 PROGRESS IN HEMATOLOGY Recent advance in the diagnosis and treatment of bone marrow failure syndromes Clinical significance of acquired somatic
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationClonality & Aplastic anemia / PNH
Clonality & Aplastic anemia / PNH What is in a word W Shakespear : Hamlet Prof G SOCIE, MD, PhD Head Division of Hematology / Immunology / Oncology French reference Center Aplastic Anemia & PNH Hospital
More informationClonal Cytopenia and Myeloid Neoplasms
Clonal Cytopenia and Myeloid Neoplasms Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation,
More informationMutations of ASXL1 and TET2 in aplastic anemia
Published Ahead of Print on February 24, 2015, as doi:10.3324/haematol.2014.120931. Copyright 2015 Ferrata Storti Foundation. Mutations of ASXL1 and TET2 in aplastic anemia by Jinbo Huang, Meili Ge, Shihong
More informationRecent advances in understanding clonal haematopoiesis in aplastic anaemia
review Recent advances in understanding clonal haematopoiesis in aplastic anaemia Natasha Stanley, 1 Timothy S. Olson 1,2 and Daria V. Babushok 1,3 1 Comprehensive Bone Marrow Failure Center, Division
More information7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?
New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More information7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure?
Personalized Medicine: tic Testing and the Implications for Future Therapies Preventiontics Michael Chicka, PhD, Molecular ticist, Preventiontics Founded in 2004 in Marshfield Wisconsin by Dr. Jim Weber
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationSession II: Summary. Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School
Session II: Summary Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School Disclosure of speaker s interests (Prefix and Last Name) (Potential) conflict
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationAplastic Anemia: Understanding Your Disease and Treatment Options
APPROXIMATE BLOOD CELL REQUIREMENTS Aplastic Anemia: Understanding Your Disease and Treatment Options Danielle Townsley, MD, MSc Associate Director, Oncology AztraZeneca Medimmune cell type total number
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationAbnormalities of the Immune System and Inflammation in MDS Pathogenesis. Shahram Kordasti MSc(Med Imm), MD, PhD Department of Haematological Medicine
Abnormalities of the Immune System and Inflammation in MDS Pathogenesis Shahram Kordasti MSc(Med Imm), MD, PhD Department of Haematological Medicine What is the role of immune system in MDS? Oligoclonal
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationPublished Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.
Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse
More informationAPPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE
APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University
More informationChronic Myelomonocytic Leukemia with molecular abnormalities SH
Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient
More informationJoint meeting ADWP & SAAWP November 2016, Paris, France
, Preliminary Programme 09 November - ADWP Educational 10:00-10:30 Welcome & coffee 1 st session Connective tissue diseases Chair: David Kiely & Renate Arnold 10:30-10:50 How do we make HSCT for SSc safer?
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationOUTCOME AFTER IMMUNOSUPPRESSION
OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University
More informationSupplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationNontransplant therapy for bone marrow failure
Nontransplant therapy for bone marrow failure Danielle M. Townsley and Thomas Winkler BONE MARROW FAILURES Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Nontransplant therapeutic
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationMyelodysplastic syndromes post ASH Dominik Selleslag AZ Sint-Jan Brugge
Myelodysplastic syndromes post ASH 2016 Dominik Selleslag AZ Sint-Jan Brugge Why did they put MDS at the end of the meeting? Possible explanations Least fascinating disease without progress? Poor speaker?
More informationAplastic anemia: Etiology, molecular pathogenesis, and emerging concepts
Received: 4 April 2018 Revised: 23 July 2018 Accepted: 24 July 2018 DOI: 10.1111/ejh.13153 REVIEW ARTICLE Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts Rory M. Shallis 1 Rami
More informationNovità nelle MDS. Matteo G Della Porta. Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy
Novità nelle MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu Outline ARCH Predictive value of somatic
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationNext generation sequencing analysis - A UK perspective. Nicholas Lea
Next generation sequencing analysis - A UK perspective Nicholas Lea King s HMDC LMH is part of an integrated pathology service at King s Haematological Malignancy Diagnostic Centre (HMDC) HMDC serves population
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health
More informationMyelodysplastic syndromes and the new WHO 2016 classification
Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationAAMDSIF. Aplastic Anemia Research Summary from the DIAGNOSIS RTEL1 Mutations and Bone Marrow Failure
AAMDSIF Aplastic Anemia Research Summary from the 2016 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A Summary of Selected Scientific Abstracts for Patients with Aplastic Anemia and Their Caregivers DIAGNOSIS
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationMyelodysplastic scoring system with flow cytometry. G Detry B Husson
Myelodysplastic scoring system with flow cytometry G Detry B Husson Myelodysplastic syndroms Clonal haematopoietic stem cell disease characterized by dysplasia in one or more of the myeloid cell lines
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationAplastic Anemia and related bone marrow failures. Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA
Aplastic Anemia and related bone marrow failures Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA CONFLICTS OF INTEREST Advisory Board meetings: Merck,
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationCase Presentation. Pei Lin, M. D.
Case Presentation Pei Lin, M. D. History A 26 yr man reports a history of numerous skin and upper respiratory infections as a child, including lymphadenitis and meningitis. In March 2013 during a preoperative
More informationAplastic anemia and clonal evolution: germ line and somatic genetics
BONE MROW FAILURES Aplastic anemia and clonal evolution: germ line and somatic genetics Akiko Shimamura Dana-Farber and Boston Children s Cancer and Blood Disorders Center, Boston, MA Clonal progression
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationClonal hematopoiesis of indeterminate potential and MDS. Siddhartha Jaiswal AAMDS Meeting 3/17/16
Clonal hematopoiesis of indeterminate potential and MDS Siddhartha Jaiswal AAMDS Meeting 3/17/16 Clonal evolution from birth to death Might pre-malignant clones, bearing only the initiating lesion, be
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationAML Genomics 11/27/17. Normal neutrophil maturation. Acute Myeloid Leukemia (AML) = block in differentiation. Myelomonocy9c FAB M5
AML Genomics 1 Normal neutrophil maturation Acute Myeloid Leukemia (AML) = block in differentiation AML with minimal differen9a9on FAB M1 Promyelocy9c leukemia FAB M3 Myelomonocy9c FAB M5 2 1 Principle
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationMyelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions
Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationSNP array based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes
MYELOID NEOPLASIA SNP array based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes *Manuel G. Afable II, 1,2 *Marcin Wlodarski, 1,3 Hideki Makishima,
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationCASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation
CASE 106 Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation Gabriel C. Caponetti, MD University of Pennsylvania, US Clinical history 69, F peripheral neuropathy, refractory
More informationMYELODYSPLASTIC SYNDROME. Vivienne Fairley Clinical Nurse Specialist Sheffield
MYELODYSPLASTIC SYNDROME Vivienne Fairley Clinical Nurse Specialist Sheffield MDS INCIDENCE 1/100,000/YEAR 3,250/YEAR MEDIAN AGE 70 MDS HYPO OR HYPERCELLULAR BONE MARROW BLOOD CYTOPENIAS (EARLY STAGES
More informationThe current perspective of low grade myelodysplastic syndrome in children
Int J Hematol (2016) 103:360 364 DOI 10.1007/s12185-016-1965-7 PROGRESS IN HEMATOLOGY Pediatric MDS/MPN The current perspective of low grade myelodysplastic syndrome in children Daisuke Hasegawa 1 Received:
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011
More informationEtiology. Definition MYELODYSPLASTIC SYNDROMES. De novo. Secondary MDS (10 years earlier than primary) transformation
MYELODYSPLASTIC SYNDROMES Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics The University of Texas M.D. Anderson Cancer Center Houston, Texas No relevant COIs to
More informationMolecular Genetic Testing to Predict Response to Therapy in MDS
Molecular Genetic Testing to Predict Response to Therapy in MDS Rafael Bejar MD, PhD Bone Marrow Failure Disease Scientific Symposium Rockville, MD March 18 th, 2016 Overview Response Criteria Lenalidomide
More informationThe Evolving Role of Transplantation for MPN
The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference
More informationBetter Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome
Better Prognosis for Patients With Del(7q) Than for Patients With Monosomy 7 in Myelodysplastic Syndrome Iris Cordoba, MD 1 ; José R. González-Porras, MD 1 ; Benet Nomdedeu, MD 2 ; Elisa Luño, MD 3 ; Raquel
More informationMyelodysplastic Syndromes:
Incidence Rate per 100,000 7/21/2015 Myelodysplastic Syndromes: Current Thinking on the Disease, Diagnosis and Treatment Rafael Bejar MD, PhD Aplastic Anemia & MDS International Foundation Regional Patient
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationScientific Symposium SUMMARY FOR PATIENTS
2016 Scientific Symposium SUMMARY FOR PATIENTS Aplastic Anemia and MDS International Foundation Greatly Appreciates the Generous Support of Our 2016 SYMPOSIUM SPONSORS This conference is supported by Grant
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More information